Clyde

Clyde Biosciences is a specialized contract research organization (CRO) and biotechnology company focused on assessing the cardiac safety and efficacy of drug candidates. Utilizing its proprietary CellOPTIQ platform, the company provides high-resolution optical measurements of action potentials and calcium transients in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). This technology allows for more accurate prediction of clinical cardiotoxicity compared to traditional electrophysiology methods like patch-clamping. Clyde Biosciences serves a global client base, including major pharmaceutical companies, helping them de-risk their pipelines early in the development process. The company's approach integrates advanced imaging with sophisticated data analysis to provide deep insights into drug-ion channel interactions. Founded as a spin-out from the University of Glasgow, it remains at the forefront of cardiac safety testing innovation.